Although several studies over the last 25 years have suggested that the GH-IGF axis is a potential therapeutic target in cancer leading to development of peptides, antibodies, and small molecules aimed at inhibiting their action, these agents have not been proven to be effective in clinical trials (15). The gene discussed is IGF1; the disease is cancer.